Full-Time
Confirmed live in the last 24 hours
EEG devices for monitoring brain activity
$165k - $195k/yr
Senior
Sunnyvale, CA, USA
Hybrid position with an in-office requirement of at least 3 times per week.
Ceribell focuses on developing medical devices that utilize electroencephalogram (EEG) technology to monitor brain activity. Their main product, the Ceribell EEG Headband and Recorder, is designed for use by trained healthcare providers in professional settings. These devices help gather important data on brain activity, which healthcare professionals can analyze to make informed treatment decisions, especially in urgent situations like Nonconvulsive Status Epilepticus (NCSE), where timely intervention is crucial. Unlike some other EEG devices, Ceribell's products do not provide diagnostic conclusions or automated alerts; they serve solely as tools for data collection. Ceribell differentiates itself by emphasizing the speed and efficiency of data gathering, which is vital in critical care scenarios. The company's goal is to enhance the ability of healthcare providers to monitor and respond to neurological conditions effectively.
Company Size
201-500
Company Stage
Series C
Total Funding
$171M
Headquarters
Mountain View, California
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Annual Bonus Opportunity
Company Equity
Phone/Internet Stipend
Barclays PLC makes new Investment in CeriBell (NASDAQ:CBLL).
CeriBell's (NASDAQ:CBLL) lock-up period ends on April 9th, allowing major shareholders and insiders to trade shares. The company issued 10,606,060 shares in its IPO on October 11th, raising $180 million at $17 per share. Analysts have given CBLL a consensus "Buy" rating with a $32.50 price target. The stock opened at $18.19, with a 52-week range of $17.24 to $32.75. Recent earnings missed estimates, reporting a loss of $0.40 per share on $18.53 million revenue.
—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions (“Ceribell”), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. “Ms
Ceribell, a former Fierce Medtech Fierce 15 honoree, has been developing a point-of-care electroencephalography platform that combines a disposable, brain-reading headset with artificial intelligence-powered algorithms that help detect hidden seizures-also known as electrographic status epilepticus, or ESE.
CeriBell, a medical device maker with an EEG platform that uses AI to monitor patient seizures, announced terms for its IPO on Monday.